Akeem Hunt Brother,
Wang Yuwen Drama List,
You Look Dapper,
Commodity Charts With Buy Sell Signals,
The World's Greatest Lover,
Lactobacillus Bulgaricus Health Benefits,
Antonio Brown Pepsi,
These forward-looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases, including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients.Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma.
from research organizations. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. Lonza will also utilize its global network of facilities, including Nansha (CN) and Visp (CH) to produce the biopolymer, and Portsmouth (US) to produce the antibody. To meet our objectives for BLA readiness and large-scale commercial supply, we are thrilled to build on an already successful partnership with Lonza. These forward-looking statements are not based on historical fact and include statements regarding the ability to commence operations at the Lonza-Kodiak Ibex facility in 2021; the ability of the Lonza-Kodiak Ibex facility to provide sufficient manufacturing capacity for the potential commercial launch of KSI-301; Kodiak’s potential BLA submission in wet AMD, DME, RVO and diabetic retinopathy in 2022; the potential licensure and commercial launch of KSI-301 in 2023; clinical and regulatory objectives and the timing thereof, expectations regarding the potential efficacy and commercial potential of Kodiak’s product candidates; and the results of our research and development efforts. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country. Kodiak is designing and developing novel therapies for the treatment of retinal diseasesAt Kodiak, we are developing disruptive products and platforms to prevent and treat the leading causes of blindnessWe aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas.Some of the statements on this site are forward-looking. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. “I’ve been passing out masks since the first siren sounded.”“Everything’s as calm as can be. The timing of this expanded partnership is designed to support Kodiak’s BLA submission timeline in 2022, and the scale is designed to support KSI-301’s potential to achieve significant market share as a new first-line agent designed to improve outcomes for patients with common and serious retinal vascular diseases.Lonza’s leadership in bioconjugation, together with experience in managing the complex supply chains under one quality system, will help Kodiak meet the precision standards required for ophthalmic intravitreal injected therapies and retinal vascular diseases in particular.
Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements.
These forward-looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases, including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients.Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma.
from research organizations. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. Lonza will also utilize its global network of facilities, including Nansha (CN) and Visp (CH) to produce the biopolymer, and Portsmouth (US) to produce the antibody. To meet our objectives for BLA readiness and large-scale commercial supply, we are thrilled to build on an already successful partnership with Lonza. These forward-looking statements are not based on historical fact and include statements regarding the ability to commence operations at the Lonza-Kodiak Ibex facility in 2021; the ability of the Lonza-Kodiak Ibex facility to provide sufficient manufacturing capacity for the potential commercial launch of KSI-301; Kodiak’s potential BLA submission in wet AMD, DME, RVO and diabetic retinopathy in 2022; the potential licensure and commercial launch of KSI-301 in 2023; clinical and regulatory objectives and the timing thereof, expectations regarding the potential efficacy and commercial potential of Kodiak’s product candidates; and the results of our research and development efforts. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country. Kodiak is designing and developing novel therapies for the treatment of retinal diseasesAt Kodiak, we are developing disruptive products and platforms to prevent and treat the leading causes of blindnessWe aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas.Some of the statements on this site are forward-looking. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. “I’ve been passing out masks since the first siren sounded.”“Everything’s as calm as can be. The timing of this expanded partnership is designed to support Kodiak’s BLA submission timeline in 2022, and the scale is designed to support KSI-301’s potential to achieve significant market share as a new first-line agent designed to improve outcomes for patients with common and serious retinal vascular diseases.Lonza’s leadership in bioconjugation, together with experience in managing the complex supply chains under one quality system, will help Kodiak meet the precision standards required for ophthalmic intravitreal injected therapies and retinal vascular diseases in particular.
Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements.